Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland
Related Experiment Video
Updated: Dec 5, 2025

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD
Published on: September 13, 2018
A J McMichael1, E Zafeiridi, M Ryan
1Centre for Public Health, Institute for Clinical Sciences Block B, Queens University Belfast, Belfast, Northern Ireland.
Insights
High anticholinergic burden from medications increases mortality risk in dementia patients. Reducing this burden is crucial, especially for those in deprived areas, to improve dementia care outcomes.
Area of Science:
- Gerontology
- Clinical Pharmacy
- Epidemiology
Background:
- Anticholinergic burden (ACB) is the cumulative effect of anticholinergic medications.
- Understanding ACB's impact on dementia patient mortality is vital for clinical practice.
- Demographic predictors of ACB in dementia patients require further investigation.
Purpose of the Study:
- To assess the influence of anticholinergic burden and specific anticholinergic drug types on mortality rates in Northern Ireland dementia patients.
- To identify demographic characteristics that predict anticholinergic burden in individuals with dementia.
Main Methods:
- Utilized prescribing data for 25,418 dementia patients (2010-2016).
- Calculated anticholinergic burden based on prescribed anticholinergic drugs.
- Employed Cox proportional hazard and multilevel regression models to analyze mortality and demographic predictors.
Main Results:
- 15% of dementia patients had no anticholinergic burden.
- Higher anticholinergic burden was significantly associated with increased mortality (HR = 1.59).
- Urological and respiratory anticholinergic drugs significantly elevated mortality risks.
- Lower anticholinergic burden was observed in dementia patients from less deprived areas.
Conclusions:
- Minimizing anticholinergic burden is essential for improving outcomes in dementia patients.
- Further research is needed to address the poorer prognosis for dementia patients in highly deprived areas.
Objective:
Anticholinergic burden refers to the cumulative effect of medications which contain anticholinergic properties. We assessed how anticholinergic burden and different types of anticholinergic medications influence mortality rates among people with dementia in Northern Ireland. Our secondary aim was to determine what demographic characteristics predict the anticholinergic burden of people with dementia.
Methods:
Data were extracted from the Enhanced Prescribing database for 25,418 people who were prescribed at least one dementia management medication between 2010 and 2016. Information was also extracted on the number of times each available anticholinergic drug was prescribed between 2010 and 2016, allowing the calculation of an overall anticholinergic burden. Cox proportional hazard models were used to determine how anticholinergic burden influenced mortality whilst multilevel model regression determined what demographic characteristics influence overall anticholinergic burden.
Results:
Of the 25,418 people with dementia, only 15% (n = 3880) had no anticholinergic burden. Diazepam (42%) and risperidone (18%) were the two most commonly prescribed drugs. Unadjusted Cox proportional hazard models indicated that higher anticholinergic burden was associated with significantly higher mortality rates in comparison to people with dementia who had no anticholinergic burden (HR = 1.59: 95% CI = 1.07-2.36). In particular, urological (HR = 1.20: 95% CI = 1.05-1.38) and respiratory (HR = 1.17: 95% CI = 1.08-1.27) drugs significantly increased mortality rates. People with dementia living in areas with low levels of deprivation had significantly lower anticholinergic burden (HR=-.39: 95% CI=-.47:-30).
Conclusions:
Reducing anticholinergic burden is essential for people with dementia. Further research should address the unfavourable prognosis of people living with dementia in highly deprived areas.
Related Concept Videos
Alzheimer's Disease: Treatment
Drug Dosing: Geriatric Patients
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Pharmacodynamics in Geriatric Patients: Effects of Age
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...